Hepatitis E virus (HEV) can cause liver disease; the main form of spread is via the fecal-oral route, through contaminated food and water. Until the discovery of HEV in 1983, it was known as Non-A, Non-B hepatitis and can be classified in four genotypes. In endemic regions, HEV infection has a fatality rate of 1 % in adolescents and young adults; mortality up to 30% was found in pregnant women. Since October 2012, a vaccine against HEV infection has been licensed in China and shows high efficacy and safety in different population groups, e.g. adults and pregnant women.
The aim of the project is to systematically assess and critically appraise existing evidence on HEV vaccine performance and to update previous summaries on this topic. Published evidence is obtained from different international data bases as well as from local Chinese data bases. Identification and evaluation of available evidence follows PRISMA guidelines and will allude to particular gaps in data availability and subsequent implications for vaccination strategies.
World Health Organization (WHO), Regional Office for the Western Pacific, Manila, Philippines;
Institut für Medizinische Informationsverarbeitung Biometrie und Epidemiologie (IBE), LMU Munich
- Epidemiology- Prof. Dr. Gérard Krause
HZI - Helmholtz Centre for Infection Research